HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells

Petri, Belinda J.; Piell, Kellianne M.; Whitt, Gordon C. South; Wilt, Ali E.; Poulton, Claire C.; Lehman, Norman L.; Clem, Brian F.; Nystoriak, Matthew A.; Wysoczynski, Marcin; Klinge, Carolyn M.

doi:10.1016/j.canlet.2021.07.015

Cited by 38 publications

(27 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Cancer type HnRNPs Expression Role Clinical correlation Detection methods Ref. MNs hnRNPA0 Downregulated Anti-cancer Pathologic differentiation Database [ 23 ] MM hnRNPA2/B1 Upregulated Oncogenic OS qRT-PCR [ 86 ] Glioblastoma hnRNPA2/B1 Upregulated Oncogenic Survival Database, qRT-PCR [ 81 ] OSCC hnRNPA1 Upregulated Oncogenic Clinicopathologic stages IHC, western blot [ 47 ] HNSCC hnRNPA2/B1 Upregulated - OS, DSS Database [ 158 ] LC hnRNPA1 Upregulated Oncogenic OS IHC, western blot, qRT-PCR [ 32 , 33 ] hnRNPA2/B1 Upregulated Oncogenic Lung development, early diagnosis, TNM stage, survival Database, IHC, western blot; northern blot [ 75 , 77 , 93 , 159 ] BC hnRNPA2/B1 Conflicting Conflicting Survival IHC, mRNA-sqe, northern blot [ 101 , 106 , 107 , 160 ] ESCA hnRNPA0 Upregulated Oncogenic …”

Section: Discussionmentioning

confidence: 99%

“…Most studies have shown that hnRNPA2/B1 was increased in BC [ 101 ], negatively correlated with cancer suppressor breast cancer susceptibility gene 1 (BRCA1) [ 102 ], and was a marker of poor prognosis in patients with BC [ 103 ]. Serving as a cancer promoter, hnRNPA2/B1 could force the autophagy, growth and endocrine resistance of BC cells [ 104 – 106 ]. In contrast, hnRNPA2/B1 was reported to be decreased in the Breast Cancer Integrative Platform and to have a dramatically inhibitory effect on the distant metastasis of TNBC [ 107 ].…”

Section: The Roles Of Hnrnpa/b In Cancers: Molecular Mechanisms and C...mentioning

confidence: 99%

See 1 more Smart Citation

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Wang

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

Heterogeneous nuclear ribonucleoprotein A/B (hnRNPA/B) is one of the core members of the RNA binding protein (RBP) hnRNPs family, including four main subtypes, A0, A1, A2/B1 and A3, which share the similar structure and functions. With the advance in understanding the molecular biology of hnRNPA/B, it has been gradually revealed that hnRNPA/B plays a critical role in almost the entire steps of RNA life cycle and its aberrant expression and mutation have important effects on the occurrence and progression of various cancers. This review focuses on the clinical significance of hnRNPA/B in various cancers and systematically summarizes its biological function and molecular mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Roles Of Hnrnpa/b In Cancers: Molecular Mechanisms and C...mentioning

confidence: 99%

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Wang

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

show abstract

“…A recent research conducted by Petri et al, which focused on endocrine resistance, suggested that HNRNPA2B1 is overexpression in primary breast tumors. Suppression of HNRNPA2B1 significantly increases TAM and fulvestrant endocrine sensitivity in TAM-resistant LCC9 and LY2 cells ( Petri et al, 2021 ). In Adriamycin (ADR)–resistant MCF-7/ADR cells augmented METTL3 increases the expression of miR-221-3p by enhancing pri-miR-221-3p maturation via accelerating m 6 A mRNA methylation.…”

Section: The Influence Of M 6 a Rna Methylation On...mentioning

confidence: 99%

The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance

Chen

Jin

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

N6-methyladenosine (m6A) RNA methylation has been considered the most prevalent, abundant, and conserved internal transcriptional modification throughout the eukaryotic mRNAs. Typically, m6A RNA methylation is catalyzed by the RNA methyltransferases (writers), is removed by its demethylases (erasers), and interacts with m6A-binding proteins (readers). Accumulating evidence shows that abnormal changes in the m6A levels of these regulators are increasingly associated with human tumorigenesis and drug resistance. However, the molecular mechanisms underlying m6A RNA methylation in tumor occurrence and development have not been comprehensively clarified. We reviewed the recent findings on biological regulation of m6A RNA methylation and summarized its potential therapeutic strategies in various human cancers.

show abstract

“…The hnRNPs superfamily proteins associated with m6A modification include HNRNPA2B1, HNRNPC, and HNRNPG. The RNA binding protein HNRNPA2B1 binds to m6A‐modified RNAs in the nucleus and mediates variable splicing of genes (Liu, Zhang, Li et al, 2020; Petri et al, 2021). Correspondingly, HNRNPA2B1 binds to the m6A site of miRNA primary transcripts, thus recruiting the miRNA microprocessing complex protein DGCR8 and facilitating further splicing of miRNA primary transcripts (Chen, Chen, Lei et al, 2020; Meng et al, 2020).…”

Section: Composition and Function Of M6a‐related Proteinsmentioning

confidence: 99%

N6‐methyladenosine (m6A) modification in gynecological malignancies

Zhang

Liu

2022

Journal Cellular Physiology

View full text Add to dashboard Cite

N6-methyladenosine (m6A) modification is one of the most abundant modifications in eukaryotic mRNA, regulated by m6A methyltransferase and demethylase. m6A modified RNA is specifically recognized and bound by m6A recognition proteins, which mediate splicing, maturation, exonucleation, degradation, and translation. In gynecologic malignancies, m6A RNA modification-related molecules are expressed aberrantly, significantly altering the posttranscriptional methylation level of the target genes and their stability. The m6A modification also regulates related metabolic pathways, thereby controlling tumor development. This review analyzes the composition and mode of action of m6A modification-related proteins and their biological functions in the malignant progression of gynecologic malignancies, which provide new ideas for the early clinical diagnosis and targeted therapy of gynecologic malignancies.

show abstract

HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells

Cited by 38 publications

References 132 publications

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance

N6‐methyladenosine (m6A) modification in gynecological malignancies

Contact Info

Product

Resources

About